NovaBay Pharma’s (NBY) Hold Rating Reaffirmed at Maxim Group
NovaBay Pharma (NYSE:NBY) traded up 2.49% on Tuesday, reaching $3.70. 23,557 shares of the company traded hands. The stock’s market capitalization is $41.63 million. NovaBay Pharma has a one year low of $1.75 and a one year high of $9.50. The firm has a 50 day moving average of $3.23 and a 200-day moving average of $2.59.
NovaBay Pharma (NYSE:NBY) last posted its earnings results on Thursday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.06. The firm had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $1.76 million. On average, analysts anticipate that NovaBay Pharma will post ($1.77) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/novabay-pharmas-nby-hold-rating-reaffirmed-at-maxim-group.html
About NovaBay Pharma
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for NovaBay Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharma and related companies with MarketBeat.com's FREE daily email newsletter.